Nitz U, et al. - Researchers assessed the efficacy of an anthracycline-free chemotherapy standard (six cycles of docetaxel and cyclophosphamide [TC]) in treating human epidermal growth factor receptor 2–negative early breast cancer (EBC) in the West German Study Group PlanB trial with patients who had pT1 to pT4c, all pN+, and pN0/high-risk EBC. The presence of one or more of the following defined high-risk pN0: pT greater than 2, grade 2 to 3, high urokinase-type plasminogen activator/plasminogen activator inhibitor-1, hormone receptor negativity, and less than 35 years of age. In a random manner, they administered to patients four cycles of epirubicin (E)90/cyclophoshamide (C)600 followed by four cycles of docetaxel (T)100 or six cycles of T75C600 (administered once every 3 weeks). Similarly excellent outcomes were seen with TC and EC-T over 5-years. Six cycles of TC in human epidermal growth factor receptor 2–negative EBC with pN0 high genomic risk or pN1 EBC with genomically intermediate- to high-risk disease was found to be an effecacious/safe option.